Can we make human plague history? A call to action by Baril, Laurence et al.
 1Baril L, et al. BMJ Global Health 2019;4:e001984. doi:10.1136/bmjgh-2019-001984
Can we make human plague history? A 
call to action
Laurence Baril,1 Xavier Vallès   ,1 Nils Christian Stenseth,2,3 
Minoarisoa Rajerison,4 Maherisoa Ratsitorahina,1 Javier Pizarro- Cerdá,5 
Christian Demeure,5 Steve Belmain,6 Holger Scholz,7 Romain Girod,8 
Joseph Hinnebusch,9 Ines Vigan- Womas,10 Eric Bertherat,11 Arnaud Fontanet,12 
Yazdan Yazadanpanah,13 Guia Carrara,13 Jane Deuve,14 Eric D'ortenzio,13,15 
Jose Oswaldo Cabanillas Angulo,16 Paul Mead,17 Peter W Horby18
Commentary
To cite: Baril L, Vallès X, 
Stenseth NC, et al. Can we 
make human plague history? A 
call to action. BMJ Global Health 
2019;4:e001984. doi:10.1136/
bmjgh-2019-001984
Handling editor Seye Abimbola
Received 11 September 2019
Revised 18 October 2019
Accepted 19 October 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Xavier Vallès;  
 xavier_ valles04@ hotmail. com
© Author(s) (or their 
employer(s)) 2019. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
Summary box
 ► In spite of the historical capacity to disrupt human 
societies, plague is currently a neglected disease.
 ► Given the resilience to be controlled in the wild, the 
focus should be put to prevent human transmission 
of plague.
 ► Research priorities include new diagnostic and ther-
apeutic tools which are urgently needed, especially 
to deal with the pulmonary form of plague.
 ► A cross- disciplinary research approach is need-
ed, including basic, ecological, clinical and social 
sciences.
InTroduCTIon
Plague is a communicable rodent- borne 
disease caused by Yersinia pestis, a Gram- 
negative bacillus member of the Entero-
bacteriaceae family. As a zoonosis, plague is 
primarily a wildlife disease hat occasionally 
spills over to the human population, resulting 
in seasonal surges in human cases and local-
ised outbreaks.1 2 The predominant clinical 
form among humans is bubonic plague, which, 
if untreated, has a lethality of 60%–90% but 
is readily treatable with antibiotics, reducing 
the death rate to around 5% if administered 
shortly after the infection.3 4 One to two 
per cent of all bubonic cases develop into 
secondary pneumonic plague, which in turn 
may be transmitted from person to person 
through respiratory droplets, producing 
primary pneumonic plague in close contacts. 
Without antibiotic treatment, pneumonic 
plague is nearly 100% fatal, but early anti-
biotic treatment substantially improves 
survival.4 Today, Y. pestis is present in at least 
26 countries, with more than 30 different flea 
vectors and over 200 mammal host species.1–3 
Although human plague cases continue to be 
reported from Asia and the Americas, most 
cases currently occur in remote, rural areas 
of sub- Saharan Africa, mostly in Democratic 
Republic of Congo and Madagascar (around 
300–500 per year).5 However, large- scale 
transmission may also occur. During the 14th 
century, the Black Death, caused by Y. pestis, 
is estimated to have killed 30%–40% of the 
European population.1
It is important to emphasise that human 
plague is mostly a poverty- related disease. 
Therefore, given that population density 
and the absolute number of people living 
in extreme poverty are both increasing in 
sub- Saharan Africa,6 there is no likelihood of 
plague being eliminated as a public health 
threat in the foreseeable future. However, the 
WHO does not consider plague to be either 
a neglected tropical disease or a ‘priority 
pathogen’ that poses a public health risk 
because of its epidemic potential.
In September 2017, an unprecedented 
urban outbreak of pneumonic plague was 
declared in Madagascar, striking primarily its 
capital Antananarivo and the major seaport of 
Toamasina.7 This episode once again brought 
international attention to plague, reminding 
us of the capacity for human plague to spread 
in urban settings and cause substantial soci-
etal and economic disruption. This should 
raise alarm bells that a research agenda is 
needed.
Improved underSTandIng of HoST–veCTor–
paTHogen InTerplay
Given the extraordinary ability of Y. pestis 
to adapt and colonise different environ-
ments, host reservoirs and vectors, and to 
re- emerge8 the elimination of plague among 
wildlife species is judged almost impossible. 
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Figure 1 Epizootic/enzootic cycles of Yersinia pestis. With permission and modified from a diagram originally produced by 
Neal R. Chamberlain.
Therefore, the focus should be put to prevent human 
transmission. The risk of human plague occurrence is 
linked to the dynamics of enzootic (maintenance in the 
wild) and epizootic (episodic amplification within and 
between mammal species, including domestic animals) 
cycles, where these dynamics remain poorly understood 
for most wildlife systems. Understanding the biology of 
host–vector–pathogen interactions and proximity to 
humans (figure 1) is a prerequisite to address apparently 
simple but not well- resolved questions regarding control 
strategies, such as the relative efficacy of using flea control 
on its own or in combination with rodent control. It is 
not just a matter of ascertaining which are the vectors, 
hosts and reservoirs involved, but also understanding the 
internal dynamics of enzootic/epizootic cycles and the 
thresholds that may lead to spillover to humans. Further-
more, the existence of other unknown host and vector 
species, the role of human ectoparasites9 and the role of 
long- term persistence in fleas, postmortem tissues or in 
the soil still remain unclear and have to be investigated.
Human beHavIourS and CommunITy engagemenT
Besides vector or rodent control measures, there are 
specific human behaviours that could be modified to 
avoid proliferation of domestic hosts, reduce contact with 
infected vectors/reservoirs and limit the potential spread 
of the disease. The diversity of human behaviours in 
different contexts may be a determinant of an epizootic 
cycle or for developing an adequate response. However, 
some aspects remain unknown, and changing deeply 
rooted cultural behaviours may be difficult. For instance, 
despite efforts for disease prevention and control, disease 
stigmatisation leading to a delay in seeking medical care 
or decisions to seek care from traditional healers can 
increase the risk of an outbreak. Of special concern is the 
connection between rural and urban areas, affecting the 
risk for the occurrence of major urban outbreaks. Special 
effort should be made towards community engagement 
to obtain their consent and cooperation for public 
health responses. For that, support from social scientists 
can provide valuable insights that can mitigate distrust, 
support cooperation and improve community communi-
cation.
ImprovemenT of dIagnoSTIC ToolS
Early and proper diagnosis of human plague victims 
is critical as delayed treatment is associated with poor 
clinical outcomes. In endemic areas, bubonic cases can 
generally be diagnosed based on clinical symptoms, 
together with the use of rapid diagnostic tests (RDTs) to 
detect F1 antigen in bubo aspirates. RDTs have been used 
successfully as an onsite diagnostic test in Madagascar 
since 2002, with positive and negative predictive values 
of 90.6% and 86.7%, respectively.10 Pneumonic cases, 
however, pose a significant diagnostic challenge in poor- 
resource settings. Data from the 2017 epidemic in Mada-
gascar suggest that there are limitations to using RDTs 
on sputum samples. Sputum samples can vary widely in 
quality, and correct processing and proper usage of the 
RDT are crucial parameters to get reliable results. Early 
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and accurate diagnosis of pulmonary plague cases is crit-
ical for detecting and controlling outbreaks, because 
pneumonic plague is the most lethal form of the disease. 
Therefore, serious consequences can arise from both 
false- negative and false- positive results. Bacteriolog-
ical methods (microscopy and culture) and molecular 
biological testing in a highly specialised laboratory are 
still necessary (ie, to improve selective media for cultiva-
tion or PCR antigen detection in blood).
ImprovemenT of CaSe managemenT
Streptomycin is highly effective and has long been consid-
ered the first choice for the treatment of most forms of 
plague. Nevertheless, it has a number of constraints, 
including adverse effects (deafness and renal toxicity), 
and must be administered carefully to children and preg-
nant women. Furthermore, since streptomycin is admin-
istered via intramuscular injection, it poses logistical 
problems in poor- resource settings. Indeed, treating a 
large number of patients with streptomycin in the context 
of an outbreak can be a major challenge. Since it is no 
longer used as a first- line treatment of tuberculosis, strep-
tomycin is not widely available, and its distribution may 
cease within a few years. In addition, the lack of specific 
clinical and reliable onsite diagnostics for pneumonic 
plague could be responsible for an important number of 
misdiagnoses and, consequently, inadequate treatment of 
common respiratory infections with streptomycin. Other 
drugs have been successfully used for the treatment of 
plague and are recommended in treatment guidelines, 
including quinolones, gentamicin, doxycycline and 
chloramphenicol.3 These recommendations are based 
on animal studies, case reports, case series and one, 
small, randomised controlled trial of doxycycline versus 
gentamicin in 2002.11 New clinical trials are needed to 
demonstrate the efficacy of antibiotics with a more attrac-
tive safety, cost and availability profile than currently 
used regimens for both the treatment and prophylaxis of 
plague. To date, antibiotic resistance in Y. pestis has been 
described in three unrelated strains isolated from rats, 
carried by plasmids which included resistances to strep-
tomycin and doxycycline.12 Therefore, given the ability 
of the Enterobacteriaceae family members to acquire any 
sort of antibiotic resistance and the extreme virulence of 
Y. pestis,13 it is essential to maintain a reliable antibiotic 
resistance monitoring system.
plague vaCCIneS
Further exploration of immunology, genetics and basic 
pathogen biology knowledge may lead to the develop-
ment of more adequate prophylaxis strategies, including 
vaccination. Vaccines against Y. pestis have been devel-
oped since the early identification of the pathogen and 
have saved many lives in Madagascar before antibiotics 
became widely available, but due to the significant side 
effects, local or systemic reactions that were sometimes 
serious, the need for revaccination and the plummeting 
of numbers of human cases, its use was abandoned. A 
number of candidates are currently under develop-
ment.14 rF1V and SV1 vaccine candidates successfully 
passed phase II trials, and the WHO recently provided 
guidance for phase III evaluation in the field.15 Ideally, a 
human plague vaccine should be effective against pneu-
monic plague and able to be rapidly distributed as a 
countermeasure in an outbreak context.
ConCluSIonS
Almost 125 years after the discovery of Y. pestis, its 
enduring threat to human health is a testament to the 
neglect of this disease. For instance, we do not have reli-
able means of rapidly diagnosing pulmonary plague nor 
a safe and effective vaccine for preventing it.The overall 
short- term focus should therefore be on specific research 
priorities that would facilitate better control of human 
plague: mapping plague risk, validation of treatment 
protocols, development of better diagnostic tools and 
vaccines and strengthening community- based interven-
tions.
A cross- disciplinary approach is needed that spans 
preclinical research to develop improved diagnostics 
and vaccines; clinical research to evaluate new diagnos-
tics, treatments and vaccines; and behavioural and social 
sciences to understand community perceptions and to 
engage communities in plague control and ecological 
sciences to better understand the determinants of enzo-
otic/epizootic cycles.
The 2017, the Madagascar pulmonary plague outbreak, 
viewed alongside the recent large- scale Ebola outbreaks 
in densely populated and extremely poor areas in Africa, 
should be taken as a serious warning. Prior to the West 
Africa Ebola tragedy, there were few indicators that a 
massive Ebola epidemic was possible. We cannot say the 
same about plague; the distant and recent history are 
both in plain sight.
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